Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 46

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 46
---
    Represents restricted stock units (“RSUs”) granted under our stockholder approved equity compensation plan referred to as the 2020 Omnibus Incentive Plan (“2020 Plan”).

    (2)
    Weighted-average exercise price is not shown as there is no exercise price for RSUs.

    (3)
    On the first anniversary date from the adoption date of the 2020 Plan (or on October 21, 2022), the total number of shares of common stock reserved for issuance under the 2020 Plan increased to 20% of the fully diluted shares of common stock outstanding, including shares of common stock reserved for issuance under convertible securities, such as the shares issuable upon the conversion of convertible preferred stock, as calculated on an as-converted basis. On October 21, 2021, the number of shares reserved for issuance under the 2020 Plan increased to 1,661,966, of which, 1,137,409 are available for future issuance.

Recent Sale of Unregistered Securities

None.

Issuer Purchases of Equity Securities

None.

    ITEM 6.
    SELECTED FINANCIAL DATA

As a “smaller reporting company” as defined
in Rule 12b-2 of the Exchange Act, selected financial data is not required to be disclosed.

 28 

    ITEM 7.
    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context otherwise requires, references
to the “Company,” the “combined company,” “Mosaic,” “we,” “our,” or “us”
in this Annual Report on Form 10-K (“Report”) refer to Mosaic ImmunoEngineering, Inc. and its subsidiaries.

The following discussion and analysis of our financial
condition and results of operations should be read in conjunction with our consolidated financial statements and related notes thereto
appearing elsewhere in this Report. 

Cautionary
Note Regarding Forward-Looking Statements

This Report, including all documents incorporated
by reference herein, includes certain statements constituting “forward-looking” statements within the meaning of Section 27A
of the Securities Act, Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995, including statements
concerning our beliefs, plans, objectives, goals, expectations, anticipations, estimates, intentions, operations, future results and prospects,
and we rely on the “safe harbor” provisions in those laws. We are including